Oncology

Because of the vulnerabilities of CDK4/6i-resistant tumors, researchers believe that it is imperative to improve the survival of this group of patients.

Rita Nanda, MD, discusses various immunotherapy drugs in the pipeline and which she thinks will be approved next. This video was filmed December 11 at the 2019 San Antonio Breast Cancer Symposium.

The rise in value-based reimbursement models has required oncology care providers to assume an unprecedented level of accountability.

The decline in the cancer mortality rate attributed to immunotherapy methods, early detection, and treatment.

After injecting the flu vaccine into a tumor cell, researchers found that the injection either slowed the growth or shrunk the tumor itself.

This medication is the first precision therapy approved to treat a genomically defined population of patients with GIST, according to Blueprint Medicines.

Officials with the FDA have approved pembrolizumab (Keytruda, Merck) for the treatment of certain patients with Bacillus Calmette-Guerin-unresponsive, high-risk, non-muscle invasive bladder cancer.

An effective treatment plan for squamous cell carcinoma best undertaken by a group of practitioners.

Since 2004, the FDA has approved different treatments for advanced prostate cancer, adding almost 2-3 indications per year for the past 15 years.

According to the study authors, such “anti-austerity agents” represent a promising approach to cancer chemotherapy.

By entering clinical and disease characteristics into a learning algorithm, researchers were able to create an efficacy prediction for CDK inhibitors.

Abemaciclib is a potent oral cyclin-dependent kinase 4/6 inhibitor that has previously demonstrated statistically significant improvement in PFS and ORR in combination with endocrine therapy.

Rita Nanda, MD, explains how researchers are aiming to make immunologically silent tumors more inflamed. This video was filmed at the 2019 San Antonio Breast Cancer Symposium.

Banu Arun, MD, explains the potential risks of passive genetic counseling via videos or at-home tests. This video was filmed December 12 at the 2019 San Antonio Breast Cancer Symposium.

Officials with the FDA have approved olaparib (Lynparza, AstraZeneca and Merck) for the maintenance treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) metastatic pancreatic adenocarcinoma whose disease has not progressed on at least 16 weeks of a first-line platinum-based chemotherapy regimen.

Researchers may have found a way to stop the driving force at a molecular level behind acute lymphoblastic leukemia.

Officials with the FDA have granted accelerated approval to fam-trastuzumab deruxtecan-nxki (Enhertu, Daiichi-Sankyo) for the treatment of adults with unresectable or metastatic HER2-positive breast cancer that have received 2 or more prior anti-HER2-based regimens in the metastatic setting.

According to results from the CORALLEEN trial presented at the San Antonio Breast Cancer Symposium, neoadjuvant treatment with the cyclin-dependent-kinase (CDK) 4/6 inhibitor ribociclib (Kisqali) and the aromatase inhibitor letrozole (Femara) produced response rates similar to multi-agent chemotherapy in patients with high-risk luminal B breast cancer.

Banu Arun, MD, explains the various reasons for the lack of genetic testing in appropriate candidates. This video was filmed December 12 at the 2019 San Antonio Breast Cancer Symposium.

Oncolytic Viral Therapy (OVT) is currently not recognized by treatment guidelines for advanced pancreatic cancer; however, safety and efficacy data from previous studies conducted over the previous 10 years have shown that OVT may be a promising, innovative approach for patients with pancreatic cancer.

A study found that the total prescriptions for gabapentinoid medications grew from 1.2 million to 3.5 million between 2005-2015.

Abemacilib is an oral selective inhibitor of cyclin-dependent kinases 4 and 6 approved for hormone receptor, human epidermal growth factor receptor 2 metastatic breast cancer.

Enfortumab vedotin-ejfv is the first FDA-approved treatment in the United States for this patient population.

A study evaluated the real-world benefit of palbociclib plus endocrine therapy as a first-line treatment in HR-positive, HER2-negative metastatic breast cancer to correlate the efficacy of the combination with neutropenia.

Patricia Spears discusses the various approaches to discussing clinical trials, and in which situations to use them. This video was filmed December 11 at the 2019 San Antonio Breast Cancer Symposium.

Researchers have confirmed that the addition of the CDK4/6 inhibitor abemaciclib to aromatase inhibitors is associated with durable tumor responses.

Dawn Hershman, MD, MS, discusses various reasons for non-adherence to endocrine therapy in breast cancer patients. This video was filmed December 13 at the 2019 San Antonio Breast Cancer Symposium.

The EGFR/RAS/MEK pathway may serve as a predictive biomarker for palbociclib plus fulvestrant resistance and offer therapeutic targets to overcome resistance in patients with ER-positive/HER2-negative breast cancer.